Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CARDIOVASCULAR AND RENAL HEMODYNAMIC-EFFECTS OF A-68930 IN THE CONSCIOUS DOG - A COMPARISON WITH FENOLDOPAM
Autore:
CHRISTIE MI; SMITH GW;
Indirizzi:
FISONS PLC,DEPT PHARMACOL,DIV PHARMACEUT,BAKEWELL RD LOUGHBOROUGH LE11 0RH LEICS ENGLAND
Titolo Testata:
The Journal of pharmacology and experimental therapeutics
fascicolo: 2, volume: 268, anno: 1994,
pagine: 565 - 570
SICI:
0022-3565(1994)268:2<565:CARHOA>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECEPTOR AGONIST FENOLDOPAM; INTRAVENOUS FENOLDOPAM; HEART-FAILURE; DOPAMINE; POTENT; HYPERTENSION; NITROPRUSSIDE; ANTAGONIST; A68930;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
M.I. Christie e G.W. Smith, "CARDIOVASCULAR AND RENAL HEMODYNAMIC-EFFECTS OF A-68930 IN THE CONSCIOUS DOG - A COMPARISON WITH FENOLDOPAM", The Journal of pharmacology and experimental therapeutics, 268(2), 1994, pp. 565-570

Abstract

The renal hemodynamic and cardiovascular effects of the novel dopamine (DA) D-1 receptor agonist A-68930 (5-6-dihydroxy-3-phenyl-1 -aminomethyl-isochroman hydrochloride) were studied in the chronically instrumented conscious dog. Intravenous infusion of A-68930, fenoldopam or DAproduced a fall in renal vascular resistance and a rise in renal blood flow (RBF), with hypotension and tachycardia. Both compounds were more potent than DA at increasing RBF. By the i.v. route, A-68930 was calculated to be 12 times more potent than fenoldopam. At the end of a submaximal infusion, the effects of A-68930 on RBF declined with a half-time of 14.8 +/- 2.5 min, significantly longer than that of fenoldopam (2.9 +/- 0.5 min) or DA (1.4 +/- 0.4 min). After p.o. dosing, A-68930 was calculated to be 84 times more potent than fenoldopam at increasing RBF. Furthermore, the A-68930-induced increase in RBF took longer to return to base line (5-6 hr) than after an equieffective p.o. dose of fenoldopam (1-2 hr). The effects of p.o. A-68930 were blocked by the DA(1) antagonist, SCH 23390 -8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-(1 H)3-benzazepine hydrochloride], consistent with an action at the DA(1) receptor. These data indicate that A-68930 is a potent, p.o.-active DA(1) agonist in the conscious dog with a longer duration ofaction than fenoldopam.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/07/20 alle ore 16:44:39